Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 422M |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
11 |
| Average PDX Generation Time (days +/- SEM) | 62 ± 4 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 422M |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | Y |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 422M | AKT1 | 0.935 | 3.823 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | AR | 1.441 | 2.714 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | CCND1 | 0.540 | 2.907 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | CDH1 | -1.645 | 0.639 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | CHD1 | -1.569 | 0.674 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | CHD7 | 0.890 | 3.708 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | FANCA | -1.422 | 0.747 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | FANCA | -1.602 | 0.659 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | IGF2R | 0.499 | 2.826 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | KDM6A | 1.044 | 2.062 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | MBD1 | -1.421 | 0.747 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | MGA | -1.646 | 0.639 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | PIK3R1 | -1.218 | 0.860 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | PIK3R1 | -1.426 | 0.745 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | SMAD2 | -1.421 | 0.747 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | ZFHX3 | -1.249 | 0.842 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 422M | ZNRF3 | -0.783 | 1.163 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 422M |
|---|---|
| Sample Site | Brain |
| Sample source | Surgery |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
| Patient Number | 422 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 422M |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 422M | TP53 | 204 | 1.0 | Splice donor variant | . | . | 33 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 422M | MGA | 158 | 0.91 | Frameshift variant | '16/24 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 422M | IGF1R | 239 | 0.5 | Missense variant | '19/21 | 2.03E-05 | 32 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 422M | CTNNB1 | 491 | 0.37 | Missense variant | '3/15 | . | 25.7 | Conflicting interpretations of pathogenicity, other | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table